Introduction
Young ovarian cancer survivors face challenging decisions about managing premature menopause symptoms after treatment. The potential risks of estrogen hormone therapy (EHT) in hormone-sensitive cancers have remained unclear. This landmark study provides critical evidence about EHT’s safety profile across different ovarian cancer subtypes in patients under 60.
